| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 408,741 | |||
| Short-term marketable securities | 59,544 | |||
| Receivables from related parties | 226 | |||
| Prepaid expense and other current assets | 7,499 | |||
| Total current assets | 476,010 | |||
| Property and equipment, net | 827 | |||
| Operating lease right-of-use asset | 2,440 | |||
| Other non-current assets | 5,384 | |||
| Restricted cash | 132 | |||
| Total assets | 484,793 | |||
| Accounts payable | 3,650 | |||
| Accrued compensation and benefits | 4,489 | |||
| Accrued research and development liabilities | 24,107 | |||
| Accrued professional services | 2,091 | |||
| Payables to related parties | 691 | |||
| Operating lease liability, current | 506 | |||
| Other accrued liabilities | 178 | |||
| Participation right liability | 0 | |||
| Total current liabilities | 35,712 | |||
| Operating lease liability, noncurrent | 2,381 | |||
| Total liabilities | 38,093 | |||
| Preference stock, value-Redeemable Convertible Preferred Stock | 0 | |||
| Preference stock, value-Preferred Stock | 0 | |||
| Common stock, 0.0001 par value 500,000,000 and 41,341,250 shares authorized as of september 30, 2025 and december 31, 2024, respectively 79,196,710 and 28,415 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 8 | |||
| Additional paid-in capital | 764,426 | |||
| Accumulated deficit | -317,770 | |||
| Accumulated other comprehensive income | 36 | |||
| Total stockholders' equity (deficit) | 446,700 | |||
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit) | 484,793 | |||
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)